The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Jun. 03, 2016
Applicant:

Aurigene Discovery Technologies Limited, Bangalore, IN;

Inventors:

Susanta Samajdar, Bangalore, IN;

Ramulu Poddutoori, Karimnagar, IN;

Chetan Pandit, Bangalore, IN;

Subhendu Mukherjee, Hooghly, IN;

Rajeev Goswami, Deharadun, IN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/40 (2006.01); A61K 45/06 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 231/56 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 471/04 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/416 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
C07D 231/40 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4155 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 231/56 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.


Find Patent Forward Citations

Loading…